Platinum Industries Limited announced its strategic entry into the life sciences sector, marking a significant milestone in the company’s next phase of growth and diversification. As part of the expansion, the company has appointed Dr. Abhigyan Upadhyay to lead its newly formed life sciences venture, Rivadu Lifesciences Pvt. Ltd.
The move reflects Platinum Industries’ broader strategy of extending its expertise from advanced chemistry solutions into applications that directly impact human health. The company said the expansion aligns with its philosophy of translating chemistry into care through innovation, quality, and responsible business practices.
Rivadu Lifesciences to Focus on Research-Driven Growth
Platinum plans to build a disciplined, research-led, and globally scalable presence across high-value life sciences segments through its wholly owned subsidiary, Rivadu Lifesciences Pvt. Ltd. The company will adopt a phased expansion strategy with an initial focus on research-driven areas such as Active Pharmaceutical Ingredients (APIs) and intermediates. In addition, Rivadu Lifesciences will work closely with strategic partners while leveraging Platinum Industries’ execution capabilities and market access strengths to establish a scalable international business model. The company also aims to build a strong presence across key global markets, including the Middle East, the United States, Europe, and Asia.
Dr. Abhigyan Upadhyay Brings Global Life Sciences Expertise
Dr. Abhigyan Upadhyay brings more than 25 years of international leadership experience spanning life sciences, regulated manufacturing, diagnostics, and research-driven business environments. Throughout his career, he has led large-scale operations and played a key role in driving transformation, growth, and market expansion across global life sciences markets. He also contributed significantly during the COVID-19 pandemic by supporting various clinical trials and research initiatives through his expertise in life sciences and healthcare technologies.
Leadership Highlights Long-Term Innovation Strategy
Krishna Dushyant Rana, Chairman and Managing Director of Platinum Industries Limited, said the company’s entry into life sciences represents a deliberate and long-term strategic move. According to Rana, the expansion allows the company to extend its philosophy of responsible chemistry into sectors that create a direct and meaningful impact on human health. He added that Dr. Upadhyay’s leadership experience brings both strategic insight and execution capability needed to develop the business in a disciplined and phased manner.
Focus on Innovation, Partnerships, and Scalable Growth
Dr. Upadhyay stated that the global life sciences industry is increasingly being shaped by the ability to convert scientific understanding into reliable, high-quality outcomes. He said the company will focus on identifying the right growth opportunities, building strategic collaborations, and introducing innovative products in a phased and sustainable manner. The broader objective, he noted, is to establish a strong foundation in research-led, high-value life sciences segments while scaling responsibly over time to support healthcare and wellbeing.
Expansion Aligns with Global Pharmaceutical Supply Chain Shift
Platinum Industries’ entry into life sciences comes at a time when global pharmaceutical supply chains are undergoing significant transformation. The company noted that demand for reliable and quality-certified manufacturing partners continues to rise worldwide, while India is increasingly emerging as a major hub for innovation-driven and high-value life sciences capabilities. As per the press release, with this expansion, Platinum Industries aims to position itself strategically within the growing global life sciences and pharmaceutical ecosystem.
